ELV's Earnings Beat Overshadowed by Medicaid Slide That Sank Stock 8.5%

Elevance Health (ELV) posted a solid quarter that beat earnings estimates, yet its stock slipped 8.5% as investors zeroed in on a deepening Medicaid crisis.

Medicaid's Bleeding: The Start of a Strategic Retreat

■Medicaid operating margin outlook remains stuck at a stark -1.75%, despite better‑than‑expected state rate updates.

■The company mutually agreed with the District of Columbia to exit its Medicaid market, signalling a broader pull‑out from additional markets over the next 12‑18 months.

■Analysts’ question — "If rates are improving, why isn’t the margin lifting?" — was met with silence, pointing to uncontrolled cost pressures.

Medicare Advantage Holds the Fort

■Medicare Advantage is on track to deliver at least a 2% operating margin this year.

■Other business lines continue to contribute positively, reinforcing the "diversified strength" narrative — at least on paper.

Guidance Raise Beneath the Surface

■Adjusted EPS came in at $7.45, well above the consensus $6.27.

■Full‑year adjusted EPS guidance was lifted to "at least $27".

■Revenue also topped estimates, but the market’s gaze fixed on the troubled segment.

Investor Reaction and Stock Move

■The share closed down 8.5%, contrasting with the strong headline numbers.

■Investors are stress‑testing the firm’s diversification claim as Medicaid losses mount.

■The announced exit strategy raises concerns about the sustainability of ELV’s current valuation and prompts a reassessment of segment‑level risk.

Ege Kaan: The persistently negative Medicaid margin exposes a structural flaw in Elevance’s otherwise diversified model; while Medicare Advantage improves, it cannot offset the drag in the near term. Market participants should re‑evaluate segment‑specific risks, adopt a defensive stance in the short run, and monitor for alternative growth drivers over the longer horizon.